Pro and Anti-Angiogenic Vascular Endothelial Growth Factors Expression in Benign and Malignant Thyroid Lesions

Eduardo Anselmo Garcia, PhD1, Kleber Simões, M.D., PhD2, Alda Wakamatsu, PhD3, Cinthya dos Santos Cirqueira, B.Sc4, Venâncio Avancini Ferreira Alves, M.D., PhD5, Adhemar Longatto-Filho, PhD, PMIAC6, Roberto Souza Camargo, M.D., PhD2

1University of São Paulo, School of Medicine, Medical Research Laboratory LIM26, São Paulo, Brazil. Paulo Prata Faculty of Health Sciences - FACISB, Barretos, Brazil
2Fellow at Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
3University of São Paulo, School of Medicine, Pathology, São Paulo, Brazil
4University of São Paulo, School of Medicine, Medical Research Laboratory LIM14, São Paulo, Brazil
5University of São Paulo, School of Medicine, Medical Research Laboratory LIM14, São Paulo, Brazil. Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal; ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
6University of São Paulo, School of Medicine, Surgery, São Paulo, Brazil. University of São Paulo, School of Medicine, Medical Research Laboratory LIM26, São Paulo, Brazil

Abstract

Vascular endothelial growth factors are the most powerful molecules related to angiogenesis and lymphangiogenesis stimulation and are frequently associated to a worse prognosis in many malignancies. Currently, anti-angiogenic VEGF-A165b has been described and it has been demonstrated to efficiently block the angiogenic sprout. We sought to investigate the VEGF family members expression involved with angiogenesis (including the anti-angiogenic VEGF-A165b) and lymph angiogenesis. The casuistic was composed by 196 cases. The frequencies of thyroid lesions were: 53 (27%) goitres, 16 (8%) thyroiditis, 9 (5%) follicular adenomas, 84 (43%) papillary carcinomas, and 34 (17%) follicular carcinomas. The immunohistochemical reactions for VEGF-A, VEGF-A165b, VEGF-B, VEGF-C and VEGF-D were performed and semi-quantitatively assessed. We observed a widespread positive immunoeexpression of VEGF-A and VEGF-A165b in benign and malignant lesions. None of the benign samples of this casuistic had positive immunoeexpression of VEGF-B and only a few positive cases were detected in both papillary and follicular carcinomas. The highest levels of VEGF-C and VEGF-D expression were found in papillary carcinomas. There was a relevant association of VEGF-D and a worst tumoral staging (p=0.004) in papillary carcinomas. We also identified a significant association between VEGF-A and vascular invasion (p=0.049) and patient’s age and an increased expression of VEGF-B (p=0.047) in papillary thyroid carcinomas. No association was found for follicular carcinomas.

Keywords: Thyroid cancer; Angiogenesis; Lymphangiogenesis; Immunohistochemistry; Vascular endothelial growth factor

Introduction

The regulation of vasculogenesis, haematopoiesis, angiogenesis, lymph angiogenesis and vascular permeability are very complex. Several molecules, such as the family of VEGFs (vascular endothelial growth factors) and other growth factors have been described as important regulators of tumour angiogenesis and lymph angiogenesis, and are thus considered important therapeutic targets [1,2]. In the early 70s, Folkman’s postulates [3] showed that angiogenesis is a crucial step of neoplastic development and a vital parameter to understanding the process of cancer biology, first for his essential role in neoplastic proliferation by supplying the energy required for tumour growth, and because of its potential as a therapeutic target. Currently several pro or anti angiogenic drugs have been approved by the FDA or are in clinical trials [4].

The family of VEGFs comprises a group of highly conserved factors regulating vasculogenesis, haematopoiesis, angiogenesis, lymph angiogenesis and vascular permeability [5,6]. The VEGF family members in mammals comprise VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PIGF). These glycoproteins belong to a super family of factors that include platelet-derived growth factor (PDGF). There are also three tyrosine kinase receptors (TKR) that belong to the family: VEGF-R1 (Flt-1), VEGF-R2 (KDR) and VEGF-R3 (Flt-4). The VEGF-R1 (vascular endothelial growth factor receptor 1) binds to VEGF-A and B, VEGF-R2 binds to VEGF-A, -C and D and VEGF-R3 binds to VEGF-C and -D [6,7]. Neuruplin -1 (NP-1) and Neuruplin -2 (NP-2) are co-receptors for some VEGF isoforms and subtypes [7].

VEGF-A is primarily related to angiogenesis while VEGF-C and VEGF-D are involved in lymph angiogenesis [8]. Little is known about the meaning of the expression of VEGF-B in tumours [5]. Recently, new isoforms generated by alternative splicing has been identified such as VEGF-A165b. Alternative splicing of the splicing distal site of exon 8 generates this isoform. Currently, it is known that VEGF-A has two isoforms of mRNA produced: the pro-angiogenic isoforms (VEGF-Axxx) and the anti-angiogenic (VEGF-Axxxb), where xxx is the number of amino acids of the mature protein. The structure of VEGF-A protein contains the dimerization sites and the heparin binding sites for VEGF-R1 and -2, which are present in all isoforms. The six amino acids from the c-terminal end of the protein will determine whether the isoform of VEGF is pro-angiogenic or anti-angiogenic. This difference promotes profound implications for the structure, interaction with receptors and function [9]. The VEGF-A165b binds with equivalent...
affinity to VEGF_A in VEGF-2 receptor; however, does not promote their activation or stimulation for subsequent signalling pathways [10].

The VEGFs are important peptides that have been widely investigated in several conditions, physiological such as the growth of the endometrium and embryonic development and pathological such as in tumour growth and metastasis [1,2,7,8,11]. The increased expression of VEGF in tumours has been associated with a poor prognosis or increased risk of recurrence or metastasis in several types of cancers [12]. In recent years some studies have demonstrated the expression of VEGF family members and its receptors in angiogenesis and lymphangiogenesis of different thyroid lesions [13-17], but the involvement of angiogenesis and lymphangiogenesis in the pathogenesis of thyroid carcinomas has not yet been elucidated. The pattern of tumour behaviour and metastasis vary with the type of tumour and has not been fully explored whether the differences in the angiogenic and lymphangiogenic phenotypes determine a more aggressive behaviour and influence tumour metastasis [13]. In addition, only few studies evaluate the expression of anti-angiogenic variants in human cancers.

The objective of the present study was to determine the immunohistochemical expression of pro-angiogenic vascular endothelial growth factors VEGF-A, VEGF-B, VEGF-C and VEGF-D, and his anti-angiogenic variant VEGF-A_165b in a series of malignant and benign thyroid lesions and correlate their expressions with the clinicopathological data.

Materials and Methods

The casuistic comprised a series of formalin-fixed, paraffin-embedded tissues from 196 patients submitted to thyroidectomy. The frequencies of different thyroid lesions were: 53 (27%) goitres, 16 (8%) thyroiditis, 9 (5%) follicular adenomas, 84 (43%) papillary carcinomas, and 34 (17%) follicular carcinomas.

The papillary carcinoma samples comprised 55 samples (65.5%) of papillary carcinoma of conventional form, 14 samples (16.7%) of follicular variant of papillary carcinoma, one sample (1.2%) of tall cell variant of papillary carcinoma, three samples (3.6%) of oxyphilic variant of papillary carcinoma, 8 samples (9.5%) of papillary micro carcinoma and 3 samples (3.6%) of follicular variant of papillary micro carcinoma. For statistical purposes, all papillary carcinomas were grouped as a single type.

All patients were submitted to surgical resection by the same surgeon (RSC) and the diagnoses were categorized according to the World Health Organization classification [18] by one of the authors (KSES).

Pathological features herein evaluated included macroscopic presentation, principal site of the tumour, histological type, and status of resection margins, vascular and capsular invasion, metastasis and TNM staging.

Tissue microarray construction

Slides from all 196 specimens were reviewed and mapped, and tissue microarrays were building using manual tissue arrayed (MTA-1 Beecher Instrument, USA). Representative areas of the thyroid lesions were selected and cores of 1.0 mm in diameter were twice sampled and arranged at 0.3 mm, one from each other, in the recipient paraffin block. A database was build for every block produced, including the coordinates of each core and case of origin.

Immunohistochemistry

The immunohistochemical expressions of VEGF-A, VEGF-A_165b, VEGF-B, VEGF-C and VEGF-D were semi-quantitatively assessed.

VEGFs protocol followed Garcia et al. [17] recommendations. Briefly, deparaffinised and rehydrated sections were immersed in 0.01 M citrate buffer (pH 6.0) and heated at 98°C for 20 min for epitope–antigen retrieval. Subsequently, endogenous peroxidase was blocked with 0.3% hydrogen peroxide in methanol. Primary antibody incubation step was done with 1:800 dilution for VEGF-A (monoclonal antibody clone VG-1, Abcam, USA), 1:50 dilution for VEGF-A_165b (monoclonal antibody clone MRVL56/1, Abcam, USA), 1:50 dilution for VEGF-B (monoclonal antibody clone 58013, R&D Systems, USA), 1:200 dilution for VEGF-C (polyclonal antibody, Zymed Laboratories, USA) and 1:200 dilution for VEGF-D (monoclonal antibody clone 78923, R&D Systems, USA), all overnight at 4°C. All primary antibodies were diluted in bovine serum albumin (BSA) (Sigma, USA) and 1.0% sodium azide Na3 (Inlab, Brazil) 0.1% in PBS buffer. The amplification method used was the polymer system Novolink (Novocastra Laboratories, UK). Visualization was developed with 3,3'-diamino-benzidine (DAKO Corporation, USA) and counterstaining with Harris haematoxylin (Merck, Germany).

Statistical analysis

The data were obtained from the available information on patient’s files and tissue samples revised. Accordingly, the statistics were based on these variables.

The relationship between VEGF-A, VEGF-A_165b, VEGF-B, VEGF-C and VEGF-D by neoplastic and non-neoplastic samples was semi-quantified under 200× magnification, considering positive reaction decorating membrane and/or cytoplasmic of normal, follicular, or malignant thyroid cells. The evaluation was performed blindly and the tissue microarray spot of each sample were fully analyzed. The following grading system was used: negative (0) absence of expression, + positive staining with expression in up to 10% of cells, ++ positive expression in over 10% up to 25% of cells, +++ positive expression in over 25% up to 50% of cells, and ++++ positive expression in over 50% of cells. For statistical analyses purposes, VEGF-A, VEGF-A_165b, VEGF-B, VEGF-C and VEGF-D expression was dichotomized in two categories: negative (0 up to 10% of positivity) and positive (over 10% of positive reaction).
years or less and for 45.8% (n = 38) was 45 or greater than this. The mean tumour size was 1.78 cm ± 1.5 (mean ± SD) and they were found predominantly in the in the right lobe (31.1%), left (24.3%) or with diffuse presentation (21.6%). Association with goitre was present in 22.6% (n = 19), with thyroïditis in 17.9% (n = 15) and both in 1.2% (n = 1) of papillary carcinomas studied. In 58.3% (n = 49) of the studied cases we did not detect any association. Capsular invasion was present in 17.9% (n = 15) of cases and was not detected in 82.1% (n = 69) and vascular invasion was observed in 16.7% (n = 14) of cases and was not detected in 83.3% (n = 70). Perithyroidal soft tissue was invaded in 10.7% (n = 9) and metastasis was detected in 13.1% (n = 11). Papillary thyroid carcinomas showed staging (TNM) I in 80.5% (n = 66), II 8.5% (n = 7), III 4.9% (n = 4) and IV A at 6, 1% (n = 5) (Table 1).

In the follicular thyroid carcinoma group women were 7.4-fold more likely to be affected than men (88.2% female and 11.8% male patients). In this patient setting the age for 55.9% (n = 19) was 45 years or less and for 44.1% (n = 15) was 45 or greater than this. The mean tumour size was 2.55 cm ± 0.98 (mean ± SD) and they were found predominantly in the in the right lobe (57.6%), left (15.2%) or with diffuse presentation (24.2%). Association with goitre was present in 17.6% (n = 6), with thyroïditis in 8.8% (n = 3) and both in 5.9% (n = 2) of follicular carcinomas studied. In 67.6% (n = 23) of the studied cases we did not detect any association. Vascular invasion was present in 26.5% (n = 6), with thyroiditis in 17.9% (n = 15) and both in 1.2% (n = 1) of cases and was not detected in 82.1% (n = 69) and IVA at 6, 1% (n = 5) (Table 1).

Illustrative photomicrographs of the immunohistochemical expression patterns obtained for VEGF-A, VEGF-A165b, VEGF-B, VEGF-C and VEGF-D in papillary and follicular carcinomas are shown in figure 1.

Our findings demonstrate a gradual increase in the intensity of immunohistochemical expression of all vascular endothelial growth factors studied from thyroid tissue with normal phenotype (data not shown), benign proliferative lesions and malignant neoplasms (Table 3). Despite the wide expression of VEGF-A in both carcinomas we have also observed a wide immunoeexpression of VEGF-A165b, the anti-angiogenic splice variant. The immunohistochemical expression of VEGFs in the adjacent peritumoral thyroid tissue was always less intense and dispersed than the observed within the tumoral area. In relation to the VEGF-B immunoeexpression we found only a few positive cases in both papillary and follicular carcinomas. The highest levels of VEGF-C and VEGF-D immunoeexpression were found in papillary carcinomas but almost all carcinomas of this study have expressed some level of VEGF-D (Table 3).

Immunohistochemical expression of VEGFs and the clinicopathological data correlation, when analyzed from 0 to ++, demonstrated a statically relevant association of VEGF-D and a worst tumoral staging (p=0.004) in papillary carcinomas. Moreover, using the dichotomized evaluation (positive or negative immunoeexpression), we also identified a weak, but statically relevant, association between VEGF-A and vascular invasion (p=0.049) and patient's age and an increased expression of VEGF-B (p=0.047) in papillary thyroid carcinomas. Clinicopathological available data and the VEGFs immunoeexpression of follicular carcinomas did not show significant statistical associations (Table 4).

In benign lesions, goitres (92% of positive cases), follicular adenomas (83% of positive cases) and thyroïditis (65% of positive cases) were observed a widespread positive immunoeexpression of VEGF-A. Positive immunoeexpression of VEGF-A165b was also founded in goitre (72% of positive cases), follicular adenomas (33% of positive cases) and thyroïditis (29% of positive cases). The immunoeexpression levels of VEGF-C and VEGF-D were generally lesser than those founded in the

Table 1: Summary of clinicopathological features in the papillary thyroid carcinomas group.

| Gender | n  | %   |
|--------|----|-----|
| (n=34) |    |     |
| M      | 4  | 11.8% |
| F      | 30 | 88.2% |

| Age | n  | %   |
|-----|----|-----|
| (n=34) |    |     |
| < 45 y.o. | 19 | 55.9% |
| > or = 45 y.o. | 15 | 44.1% |

| Size (cm) Mean (± SD) | n  |
|----------------------|----|
| 2.55 ± 0.98          |    |

| Vascular Invasion | n  | %   |
|------------------|----|-----|
| (n=34) |    |     |
| Present | 9  | 26.5% |
| Non-detected | 25 | 73.5% |

| Perithyroidal Soft Tissue Compromise | n  | %   |
|-----------------------------------|----|-----|
| (n=34) |    |     |
| Present | 2  | 5.9% |
| Non-detected | 32 | 94.1% |

| Metastasis | n  | %   |
|------------|----|-----|
| (n=34) |    |     |
| Non-detected | 34 | 100% |

| Staging (TNM) | n  | %   |
|---------------|----|-----|
| (n=34) |    |     |
| I | 22 | 64.7% |
| II | 10 | 29.4% |
| III | 2  | 5.9% |

Table 2: Summary of clinicopathological features in the follicular thyroid carcinomas group.
angiogenic and lymphangiogenic, in thyroid neoplasms [13,19]; this lesions. These findings corroborate previous studies that verified an members have a tendency to be higher in malignant than in benign expressions was applied. Generally, the expression of VEGF family malignant thyroid lesions, which were more evidently established when expression of VEGFs family members among a varied of benign and Discussion

The results of this study demonstrated significant differences in the expression of VEGFs family members among a varied of benign and malignant thyroid lesions, which were more evidently established when a dichotomized positive or negative score of immunohistochemical expressions was applied. Generally, the expression of VEGF family members have a tendency to be higher in malignant than in benign lesions. These findings corroborate previous studies that verified an increased expression of vascular endothelial growth factors, both angiogenic and lymphangiogenic, in thyroid neoplasms [13,19]; this carcinomas. None of the benign samples of this casuistic had positive immunoexpression of VEGF-B (Figure 1).

Most VEGFs were widely and strongly immunoexpressed in both papillary and follicular carcinomas. In these neoplasms the number of cases with immuno-positive expression for VEGF-A, VEGF-A$_{165b}$, VEGF-C and VEGF-D was higher than 75% reaching 100% of positive cases for VEGF-D in papillary carcinomas. Only VEGF-B showed a weak immunoexpression, with only 8% of positive cases in the papillary carcinomas and 9% in follicular carcinoma.

Both types of tumours have showed significant differences between the VEGF-A immunohistochemical expression in the neoplastic area when compared to its expression in areas of thyroiditis, goitre and morphologically normal adjacent tissue. This finding is relevant because higher expression of VEGF-A is often associated with tumour growth due to its potential contribution for providing nutrients for cell proliferation. In agreement with other articles in the literature, our study demonstrates that the levels of immunoexpression of VEGF-A in morphologically normal adjacent regions is lower than that found in the papillary and follicular neoplasms of the thyroid [21]. We demonstrate that almost 100% of papillary and follicular carcinomas showed immunohistochemical positive expression of VEGF-A in cancer cells. In contrast, 81% of papillary carcinomas and 84% of follicular carcinomas express VEGF-A$_{165b}$, an isofrom that inhibit angiogenesis [9]. So far we are not aware of any other paper that has described the participation of VEGF-A$_{165b}$ in thyroid neoplasms; this interesting observation may explain, at least in part, the indolent behaviour of most thyroid carcinomas and demonstrates the existence of a balance between pro and anti-angiogenic factors. We could not observe variations in the immunohistochemical expression of VEGF-A$_{165b}$ in different variants of papillary carcinoma. In adjacent tissues with phenotypeormal thyroid, goitre or thyroiditis VEGFs immunoexpression were always inferior to those found in the neoplastic region. Nevertheless, the expression of VEGF-A was quite expressive. Thyroiditis and goitre express high amounts of TSH (thyroid stimulating hormone), firstly because of the destruction of follicles, and secondly because of deficiency on thyroid hormone synthesis mostly caused by deficiency in iodine supply. Both changes lead to increased TSH, admittedly, an important regulator of VEGF-A expression [22]. This fact potentially explains the high levels of VEGF-A observed in adjacent regions of papillary and follicular carcinomas containing goitre and thyroiditis. Moreover, the high immunoexpression of the main mediator of angiogenesis, VEGF-A, is consistent with the significant increase in the neovascularisation observed in chronic inflammation and also with the fact of the thyroid, because of their endocrine functions, require a precise regulation of their microvasculature [23]. According to Klein and Catargi [23], thyroid inflammatory processes may be accompanied by the development of vasculature and increased vascular permeability, which explains the swelling usually observed in thyroiditis. In agreement with our findings, significant levels of VEGF-A expression in different etiologic thyroiditis types have been reported in the literature [24]. Angiogenesis mediated by VEGF-A is particularly related to inflammatory reactions as a whole, because inflammatory cytokines (including those involved with thyroiditis) are mediators of VEGF-A expression, such as for example interleukin-6 [25]. Although high levels

![Figure 1: Positive immunohistochemical expression patterns obtained in papillary carcinoma (left) for VEGF-A (A1 – 40X), VEGF-A$_{165b}$ (B1 – 40X), VEGF-B (C1 – 40X), VEGF-C (D1 – 40X) and VEGF-D (E1 – 40X) and positive immunohistochemical expression patterns obtained in follicular carcinoma (right) for VEGF-A (A2 – 40X), VEGF-A$_{165b}$ (B2 – 40X), VEGF-B (C2 – 40X), VEGF-C (D2 – 40X) and VEGF-D (E2 – 40X).](image-url)
immunoexpression of VEGF-A165b was also found in these areas adjacent to thyroid papillary and follicular carcinomas, an important feature in non neoplastic lesions, and even in morphologically normal tissues of immunohistochemical positivity expression for VEGF-A were found in thyroid carcinomas, and follicular adenomas.

Table 3: Percent and number of negative and positive VEGF-A, VEGF-A165b, VEGF-B, VEGF-C and VEGF-D expression cases among papillary carcinomas, follicular thyroid carcinomas, and follicular adenomas.

|                | VEGF-A | VEGF-A165b | VEGF-B | VEGF-C | VEGF-D |
|----------------|--------|------------|--------|--------|--------|
|                | Negative (< 10%) | Positive (> or equal 10%) | Negative (< 10%) | Positive (> or equal 10%) | Negative (< 10%) | Positive (> or equal 10%) | Negative (< 10%) | Positive (> or equal 10%) | Negative (< 10%) | Positive (> or equal 10%) | n |
| Papillary Carcinoma | 3 (5%) | 63 (96%) | 66 | 12 (19%) | 51 (81%) | 63 | 58 (92%) | 5 (8%) | 63 | 9 (14%) | 56 (86%) | 65 | 0 | 66 (100%) | 66 |
| Follicular Carcinoma | 2 (11%) | 17 (90%) | 19 | 3 (16%) | 16 (84%) | 19 | 21 (91%) | 2 (9%) | 23 | 5 (22%) | 18 (78%) | 23 | 4 (17%) | 19 (83%) | 23 |
| Goiter | 4 (8%) | 47 (92%) | 51 | 14 (28%) | 36 (72%) | 50 | 49 (100%) | 0 | 49 | 33 (65%) | 18 (35%) | 52 | 11 (22%) | 38 (78%) | 49 |
| Thyroiditis | 6 (35%) | 10 (65%) | 16 | 11 (71%) | 5 (29%) | 16 | 16 (100%) | 0 | 16 | 6 (35%) | 10 (65%) | 16 | 6 (35%) | 10 (65%) | 16 |
| Follicular Adenoma | 1 (17%) | 5 (83%) | 6 | 4 (67%) | 2 (33%) | 6 | 6 (100%) | 0 | 6 | 5 (83%) | 1 (17%) | 6 | 4 (67%) | 2 (33%) | 6 |

Table 4: Comparison between VEGFs immunoexpression and clinicopathological features.

|                | VEGF-A | VEGF-A165b | VEGF-B | VEGF-C | VEGF-D |
|----------------|--------|------------|--------|--------|--------|
|                | p      | p          | p      | p      | p      |
| Age | 0.852 | 0.447 | 0.047* | 0.642 | - |
| Gender | 0.454 | 0.793 | 0.326 | 0.168 | - |
| Side | 0.300 | 0.090 | 0.197 | 0.095 | - |
| Capsular Invasion | 0.654 | 0.518 | 0.207 | 0.359 | - |
| Vascular Invasion | 0.049* | 0.706 | 0.945 | 0.412 | - |
| Perithyroidal Soft Tissue Compromise | 0.309 | 0.793 | 0.355 | 0.433 | - |
| Metastasis | 0.428 | 0.936 | 0.298 | 0.648 | - |
| T | 0.707 | 0.263 | 0.671 | 0.949 | - |
| N | 0.763 | 0.794 | 0.723 | 0.758 | - |
| M | - | - | - | - | - |
| Staging | 0.905 | 0.582 | 0.809 | 0.321 | - |

|                | FolkV Carcinoma | VEGF-A | VEGF-A165b | VEGF-B | VEGF-C | VEGF-D |
|----------------|----------------|--------|------------|--------|--------|--------|
|                | p      | p          | p      | p      | p      |
| Age | 0.937 | 0.466 | 0.156 | 0.538 | 0.315 |
| Gender | 0.608 | 0.517 | 0.567 | 0.602 | 0.435 |
| Side | 0.266 | 0.439 | 0.704 | 0.515 | 0.093 |
| Vascular Invasion | 0.08 | 0.348 | 0.636 | 0.433 | 0.482 |
| Perithyroidal Soft Tissue Compromise | 0.725 | 0.656 | 0.752 | 0.052 | 0.639 |
| Metastasis | - | - | - | - | - |
| T | 0.811 | 0.354 | 0.706 | 0.791 | 0.89 |
| N | - | - | - | - | - |
| M | - | - | - | - | - |
| Staging | 0.597 | 0.440 | 0.558 | 0.780 | 0.275 |

The VEGF-C expression shown in this study corroborated previous reports that observed that VEGF-C is more importantly expressed in papillary carcinoma than in other thyroid malignancies [15,28]. VEGF-C is the most important lymphangiogenic stimulation factor [1]. Its overexpression is consistently associated to lymph node invasion and distant metastasis [29,30]. However, the role of VEGF-C in thyroid carcinomas as prognostic marker is still disputable [17,31]. Similarly, VEGF-D expression was reported in thyroid carcinoma, mainly in those with papillary phenotype [16]. This is in agreement with our results that demonstrated that all papillary carcinomas and 83% of follicular carcinomas stained for VEGF-D. Non-neoplastic lesions were also decorated with VEGF-D, which limits its importance for prognostic proposals. Of interest, our results corroborates previous reports that showed higher expression of VEGF-D in papillary than in follicular carcinomas, which seems to be logical because papillary carcinomas preferentially metastasise through lymphatic conduits [23]. Additionally, VEGF-D expression is more likely correlated with augmented risk for lymph node invasion and distant metastasis [16,23].

Summarising, despite higher VEGF-A expression be commonly
associated to the problems of worse prognosis in literature, some controversial results were herein reported. First, as other reports, we did not find any important correlation between tumour size and more aggressive behaviour [13,32,33]; neither as an independent marker for lymph node invasion or distant metastasis [34]. Our findings corroborated those found by Huang and colleagues [35] that did not find any association between VEGF-A and tumour size, tumour extension, invasion and AGES (Patient’s age, tumour size; histological grade, tumoral extension and metastasis) or MACIS (metastasis, age, resection margin, invasion and tumour size). VEGF-A, b was importantly expressed in thyroid carcinomas and it seems act like a balance against the VEGF-A pro-angiogenic force. Since we still do not understand which and how factors induce the selection of those splicing variants the real meaning of this expression (in both benign and malignant cases) is still obscure and should be ratified in further studies.

Acknowledgements

We thank the supply of the histological samples by the histopathology laboratories of Sírio Libanés Hospital, Oswaldo Cruz Hospital CICAP, Diagnóstica Laboratory and the technical support of the Medical Research Laboratories (14 (LIM-14) and 26 (LIM-26) of Faculty of Medicine of São Paulo University. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

1. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
2. Adams RH, Altalot K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-478.
3. Folkman J (1971) Tumor angio genesis: therapeutic implications. N Engl J Med 285: 1182-1186.
4. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
5. Niki T, Ibii S, Tokoumi M, Yamada T, Matsuno Y, et al. (2000) Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6: 2431-2439.
6. Pepper MS (2001) Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 7: 462-468.
7. Yamazaki Y, Morita T (2006) Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 10: 515-527.
8. Byrne AM, Bouchier-Hayes DJ, Harmsy JM (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794.
9. Harper SJ, Bates DO (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887.
10. Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF) VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (London) 109: 227-241.
11. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 699-676.
12. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, et al. (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86: 656-658.
13. de la Torre NG, Buley I, Wass JA, Turner HE (2008) Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 15: 931-944.
14. Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, et al. (2002) Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg Today 32: 761-768.
15. Hung CJ, Girzinger DG, Zarnegar R, Kanauchi H, Wong MG, et al. (2003) Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab 88: 3694-3699.
16. Yashiro H, Nakamura Y, Zuo H, Tang W, Kakamura Y, et al. (2005) VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18: 1127-1133.
17. Garcia EA, Simões K, Wakamatsu A, Cirqueira CD, Alves VAF, et al. (2010) Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol 21: 101-107.
18. DeLeiris RA, Vitroy R, Heitz PU, Eng C (2004) World Health Organization classification of tumours pathology and genetics of tumours of endocrine organs.
19. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, et al. (1999) Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161: 41-49.
20. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25.
21. Jebrael A, Englund J, Bedford K, Murphy J, Karsal L, et al. (2007) Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88: 271-277.
22. Ramsden JD (2000) Angiogenesis in the thyroid gland. J Endocrinol 166: 475-480.
23. Klein M, Catargi B (2007) VEGF in physiological process and thyroid disease. Ann Endocrinol (Paris) 68: 438-448.
24. Klein M, Brunaud L, Muresan M, Barbé F, Marie B, et al. (2006) Recombinant human thyrotropin stimulates thyroid angiogenesis in vivo. Thyroid 16: 531-536.
25. Cohen T, Nahari D, Cerem LW, Neufield G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741.
26. Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62: 179-213.
27. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, et al. (2009) VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A 106: 6152-6157.
28. Lin JD, Chao TC (2005) Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm 20: 649-661.
29. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, et al. (2003) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89: 426-430.
30. Nisato RE, Tille JC, Pepper MS (2003) Lymphangiogenesis and tumor metastasis. Thromb Haemost 90: 591-597.
31. Longatto-Filho A, Pinheiro C, Ferreira L, Scapulatempo C, Alves VA, et al. (2008) Peritumoral, but not intratumoral, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers. Virchows Arch 452: 133-138.
32. Bunorne G, Vignet P, Mariani L, Bulto S, Collini P, et al. (1999) Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155: 1967-1976.
33. Fenton C, Patel A, Dinsaur C, Robie DK, Tuttle RM, et al. (2000) The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10: 349-357.
34. Kilicarslan AB, Ogos M, Arici C, Pestereli HE, Cakir M, et al. (2003) Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 111: 439-443.
35. Huang SM, Lee JC, Wu TJ, Chow NH (2001) Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 25: 302-306.